Kairos Pharma presents preclinical data for KROS 101 and KROS 401 at AACR IO

Kairos Pharma, LTD.

KROS 101 (GITR agonist) inhibited tumor growth in melanoma model and increased CD4+/CD8+ T cell proliferation.
KROS 101 prevented T cell exhaustion, a key advantage over prior GITR antibody TRX518.
KROS 401 peptide inhibitor reduced M2 macrophages and showed anti-tumor effect in glioma-bearing mice.
Data presented at AACR Immuno-Oncology conference in Los Angeles, February 23-26, 2025.
CEO highlighted potential of KROS platform to address T cell exhaustion and reprogram tumor microenvironment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.